Retrophin, Inc. (RTRX) Forecasted to Earn FY2017 Earnings of ($1.29) Per Share

Retrophin, Inc. (NASDAQ:RTRX) – Analysts at William Blair decreased their FY2017 earnings per share estimates for shares of Retrophin in a report issued on Wednesday. William Blair analyst T. Lugo now expects that the biopharmaceutical company will post earnings of ($1.29) per share for the year, down from their prior forecast of ($1.18). William Blair also issued estimates for Retrophin’s Q4 2017 earnings at ($0.29) EPS, FY2018 earnings at ($1.54) EPS, FY2019 earnings at ($0.75) EPS and FY2020 earnings at $2.07 EPS.

Several other equities research analysts have also recently weighed in on RTRX. ValuEngine cut Retrophin from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. BidaskClub upgraded Retrophin from a “hold” rating to a “buy” rating in a research report on Wednesday, August 16th. BMO Capital Markets reiterated a “buy” rating and set a $44.00 price target on shares of Retrophin in a research report on Friday, October 6th. Finally, Zacks Investment Research cut Retrophin from a “hold” rating to a “strong sell” rating in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $36.00.

COPYRIGHT VIOLATION NOTICE: “Retrophin, Inc. (RTRX) Forecasted to Earn FY2017 Earnings of ($1.29) Per Share” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at https://sportsperspectives.com/2017/11/15/retrophin-inc-rtrx-forecasted-to-earn-fy2017-earnings-of-1-29-per-share.html.

Shares of Retrophin (NASDAQ RTRX) opened at $21.34 on Monday. Retrophin has a 52-week low of $15.55 and a 52-week high of $26.44. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.83 and a current ratio of 3.88.

Retrophin (NASDAQ:RTRX) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.21). Retrophin had a negative net margin of 33.79% and a negative return on equity of 10.13%. The company had revenue of $40.34 million for the quarter, compared to the consensus estimate of $40.51 million. During the same quarter in the prior year, the company earned ($0.09) earnings per share. The company’s quarterly revenue was up 18.8% on a year-over-year basis.

Several hedge funds have recently bought and sold shares of the stock. Perceptive Advisors LLC increased its position in shares of Retrophin by 0.5% in the third quarter. Perceptive Advisors LLC now owns 2,686,204 shares of the biopharmaceutical company’s stock worth $66,859,000 after purchasing an additional 13,895 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Retrophin by 8.3% in the second quarter. Vanguard Group Inc. now owns 1,635,234 shares of the biopharmaceutical company’s stock worth $31,707,000 after purchasing an additional 125,695 shares during the last quarter. Macquarie Group Ltd. increased its position in shares of Retrophin by 22.7% in the third quarter. Macquarie Group Ltd. now owns 1,459,218 shares of the biopharmaceutical company’s stock worth $36,320,000 after purchasing an additional 270,399 shares during the last quarter. Oak Ridge Investments LLC increased its position in shares of Retrophin by 96.9% in the second quarter. Oak Ridge Investments LLC now owns 1,022,871 shares of the biopharmaceutical company’s stock worth $19,833,000 after purchasing an additional 503,428 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Retrophin by 8.7% in the third quarter. Dimensional Fund Advisors LP now owns 896,815 shares of the biopharmaceutical company’s stock worth $22,322,000 after purchasing an additional 71,562 shares during the last quarter.

About Retrophin

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Earnings History and Estimates for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply